ArticleJournal of cancer research and clinical oncology2022

Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.

Jing-Jing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.